A newly developed software called Datinrad has combed through extensive literature and compiled more than two hundred radiopharmaceutical interactions and adverse effects is now accessible through a single PC portal, according to an article published July 15 in the Journal of Nuclear Medicine Technology.

In the largest, multicenter study of incidental findings on CT in pediatric blunt head trauma, about 4 percent of children had nontraumatic incidental findings, according to a study published July 22 in Pediatrics.

Not at all, according to a commentary published in the August issue of Radiology. The overdiagnosis myth overshadows the real problems—suboptimal patient management and overtreatment. The authors urged imagers to remain vigilant in detection and suggested they play an active role in management decisions.

North Carolina joins 11 other states to become the 12th state to standardize dense breast tissue reporting to women across the state.

A Swedish initiative to spur appropriate imaging use in prostate cancer by providing utilization data and guidelines to clinicians caused the rate of inappropriate scans for low-risk patients to nose-dive, according to a study published online July 23 in the Journal of the National Cancer Institute.

Differences in breast cancer survival rates among black and white women have barely budged in the last two decades, researchers reported in the July 24/31 issue of JAMA. Demographics, health and tumor biology account for most of the difference, they found. Specifically, black women had less access to primary care and breast cancer screening.

Standard methods of evaluation for Alzheimer’s disease (AD) including cognitive tests and one-time PET imaging do not provide a bird’s eye view of disease development. A technique combining a range of examinations and a series of F-18 FDG PET studies is providing researchers valuable information about AD formation, according to research published July 12 in the Journal of Nuclear Medicine.

The predictive value of FDG PET for therapy response has been proven for a range of treatments for non-small cell lung cancer (NSCLC), now including concomitant chemoradiotherapy, which requires careful patient selection due to associated morbidity, according to a study published July 17 in the Journal of Nuclear Medicine.